Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 28, 2015 11:04 AM ET


Company Overview of EPIRUS Biopharmaceuticals, Inc.

Company Overview

EPIRUS Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company’s pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment ...

699 Boylston Street

8th Floor

Boston, MA 02116

United States

33 Employees



Key Executives for EPIRUS Biopharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 47
Total Annual Compensation: $428.1K
Chief Financial Officer, Senior Vice President and Treasurer
Age: 55
Total Annual Compensation: $292.7K
Chief Technical Officer and Senior Vice President
Age: 59
Total Annual Compensation: $294.2K
Compensation as of Fiscal Year 2014.

EPIRUS Biopharmaceuticals, Inc. Key Developments

EPIRUS Biopharmaceuticals, Inc Provides Clinical Program Update on BOW015

EPIRUS Biopharmaceuticals, Inc. announced the completion of manufacturing process lock and readiness for initiation of its pivotal global registration study. EPIRUS plans to initiate a global registration study for BOW015 (infliximab, reference biologic Remicadeii) in active Rheumatoid Arthritis (RA) patients in the United States, Europe and other markets in the first quarter of 2016. The company is on track for a harmonized global filing for marketing approval for BOW015 in 2017. EPIRUS continues to compile a comprehensive data package that will serve as the basis for the global filing. The forthcoming global registration study will build on positive data from EPIRUS' Phase 1 study in healthy volunteers conducted in the United Kingdom and Phase 3 study in active RA patients, which were presented at recent American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) meetings. These data reinforce the pharmacokinetic, safety and efficacy profile for BOW015, which further demonstrate the biosimilarity between BOW015 and Remicade. To date, between the clinical and market experience, nearly 750 patients have been treated with BOW015.

EPIRUS Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015

EPIRUS Biopharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported revenue was $221,000 compared with Nil a year ago. Loss from operations was $14,042,000 against $13,929,000 a year ago. Net loss was $13,987,000 against $13,935,000 a year ago. Basic and diluted loss per share was $0.59 against $1.28 a year ago. For the nine months, the company reported revenue was $291,000 compared with Nil a year ago. Loss from operations was $36,272,000 against $29,100,000 a year ago. Net loss was $36,794,000 against $31,445,000 a year ago. Basic and diluted loss per share was $1.66 against $8.15 a year ago.

EPIRUS Biopharmaceuticals, Inc. Appoints Vincent E. Aurentz as Chief Business Officer

EPIRUS Biopharmaceuticals, Inc. announced that Vincent E. Aurentz has joined the Company as Chief Business Officer. Aurentz most recently served as the President of HemoShear Therapeutics, where he oversaw the scientific and business development efforts including collaborations with global organizations such as Pfizer, Eli Lilly, Janssen R&D and Children's National Health System. Prior to joining HemoShear Therapeutics, Mr. Aurentz was Executive Vice President and member of the Executive Management Board at Merck KGaA (Merck Serono) where he directed R&D programs, portfolio strategy and headed all deal activity and venture investments.

Similar Private Companies By Industry

Company Name Region
ImmunoNewco, Inc. United States
Genevolve Vision Diagnostics, Inc. United States
Samumed, LLC United States
Retrotope, Inc. United States
Calibrant Biosystems, Inc. United States

Recent Private Companies Transactions

October 7, 2015
Zalicus Pharmaceuticals Ltd.
September 9, 2015
Bioceros Holding B.V.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EPIRUS Biopharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at